In 2014, renal denervation procedures to treat resistant hypertension took a crippling blow, when Medtronic failed to meet the primary endpoints in a trial, but recent activity from the Dublin-based firm and others indicates that the space is hot once again.
News & Features
MIT researchers have discovered a way to potentially restore movement in patients with paralysis, or treat unwanted movements such as muscle tremor in Parkinson's patients.
A recently-published meta-analysis showed higher mortality rates with Paclitaxel drug-coated balloons and drug-eluting stents, and at least two drug-eluting device trials have been paused.
FDA’s nod for the Sapien 3 Ultra valve comes at a time when the TAVR market is heating up with competition.
The obesity treatment market has been through some changes lately and Obalon’s new funding deals could help the company navigate through some of these shifts and keep competitors at bay.
Infervision’s deep-learning system alerts radiologists to the possible presence of four different diseases, which could lead to faster and more comprehensive diagnoses.
The Marlborough, MA-based company strengthens its structural heart portfolio and gains a deeper foothold in a market where Medtronic, Abbott Laboratories, and Edwards Lifesciences have already made significant acquisitions.
With the explosion of artificial intelligence and its overall acceptance in healthcare along with strong data supporting the WATS3D test, could 2019 be a breakthrough year for CDx Diagnostics.
From the launch of a rapid point-of-care flu test to layoffs and warning letters, these were the most popular news stories on MD+DI in 2018.
Bayer has already decided to stop selling the controversial birth control device, but FDA says it will continue to monitor the long-term safety of Essure.
The Braintree, MA-based firm’s Paragonix SherpaPak Cardiac Transport System also has clearance for the adult patient population.